Genomic characterization of ependymomas reveals 6q loss as the most common aberration

THAILE KRISTIN OLSEN1-3, LUDMILA GORUNOVA1,2, TORSTEIN R. MELING4, FRANCESCA MICCI1,2, DAVID SCHEIE5, BERNT DUE-TØNNESSEN4, SVENRE HEIM1-3 and PETTER BRANDAL1,2,6

1Section for Cancer Cytogenetics, Institute for Cancer Genetics and Informatics, Oslo University Hospital - The Norwegian Radium Hospital, Nysalen, 0424 Oslo; 2Centre for Cancer Biomedicine, Faculty of Medicine, University of Oslo, The Norwegian Radium Hospital, Nysalen, 0424 Oslo; 3Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Blindern, 0316 Oslo; Departments of 4Neurosurgery, 5Pathology, Oslo University Hospital - Rikshospitalet, Nysalen, 0424 Oslo; 6Department of Oncology, Oslo University Hospital - The Norwegian Radium Hospital, Nysalen, 0424 Oslo, Norway

Received March 7, 2014; Accepted April 17, 2014

DOI: 10.3892/or.2014.3271

Abstract. Ependymomas are rare tumors of the central nervous system (CNS). They are classified based on tumor histology and grade, but the prognostic value of the WHO grading system remains controversial. Treatment is mainly surgical and by radiation. An improved knowledge of ependymoma biology is important to elucidate the pathogenesis, to improve classification schemes, and to identify novel potential treatment targets. Only 113 ependymoma karyotypes with chromosome aberrations are registered in the Mitelman database. We present the first study of ependymoma genomes combining karyotyping and high resolution comparative genomic hybridization (HR-CGH). Nineteen tumor samples were collected from three pediatric and 15 adult patients treated at Oslo University Hospital between 2005 and 2012. Histological diagnoses included subependymoma and myxopapillary ependymoma (WHO grade I), ependymoma (WHO grade II) and anaplastic ependymoma (WHO grade III). Four tumors were intraspinal and 15 were intracranial. Seventeen samples were successfully karyotyped, HR-CGH analysis was undertaken on 17 samples, and 15 of 19 tumors were analyzed using both methods. Twelve tumors had karyotypic abnormalities, mostly gains or losses of whole chromosomes. Structural rearrangements were found in four tumors, in two of which 2p23 was identified as a breakpoint region. Twelve tumors displayed genomic imbalances by HR-CGH analysis with loss of material at 6q as the most common. 6q loss, which was detected by one or both methods in seven of 12 (58%) abnormal tumors, and 5p gain (observed in five tumors; 42%) were the most common genomic aberrations in this series.

Introduction

Ependymomas are primary neuroepithelial tumors of the central nervous system (CNS) mimicking ependymal cell differentiation. Intraspinal ependymomas are more common in the adult patient population whereas children more often have intracranial tumors (1). Ependymomas are subgrouped into subependymomas (WHO grade I), ependymoma (WHO grade II) and anaplastic ependymoma (WHO grade III) (2). They are rare with an incidence of ~2 per million inhabitants per year (3). Ependymomas of grades II and III constitute 2-5% (4-7) of all primary CNS neoplasms and only 1-3% of brain tumors in adults (6,8). However, they are the fourth most common CNS neoplasm in children, constituting 6-12% of all intracranial pediatric tumors. Within the pediatric population, more than a third of the patients are 4 years of age or younger (2,4,6).

Surgery is the mainstay of ependymoma treatment and gross total tumor resection (GTR) is an independent prognostic factor affecting both overall (OS) and progression-free (PFS) survival (2,6,8-10). GTR is only achieved in ~50-75% of patients, however (8-10). The 5-year relative survival of ependymoma patients is reported to be ~70% (11,12) and children tend to fare worse than adults (13,14). Patients with intraspinal tumors have a better prognosis than those with intracranial tumors (2,6,13,15) and some studies indicate that supratentorial ependymomas carry a worse prognosis than infratentorial lesions (13,16-19). Grade I ependymomas have a relatively good prognosis (2) whereas the histologic distinction between ependymoma grade II and III is a controversial issue of unclear prognostic importance (2,3,15,20-22). Genetic and molecular characteristics of these tumors may prove to be more reliable prognostic markers (15,23).
Only 113 ependymomas (of 2,511 CNS tumors) are registered in the Mitelman Database of Chromosome Aberrations in Cancer (24). Approximately two-thirds of ependymomas are karyotypically abnormal (25) and most of these are near-diploid (24,26). Loss of chromosome 22 has been the most common aberration (25,27) reported in approximately a third of tumors with abnormal karyotypes, with structural abnormalities of chromosome 22 being reported in another 11% (3,24). In a large meta-analysis (23) comparing CGH results in adult and pediatric ependymomas, chromosome 22 was the most common site of genomic loss in both groups. Ig gain was significantly more frequent in the pediatric tumors and was the most common aberration overall in this group. Gains of chromosomes 7, 9 and 12 were significantly more common in adult tumors which also had a higher number of genomic imbalances than did pediatric ependymomas. Thus, the authors suggested that ependymomas of the two age groups are genetically distinct.

No previous studies have investigated the ependymoma genome using a combination of CGH and G-banding techniques. We describe genomic and chromosomal aberrations in a series of histologically heterogeneous ependymomas.

Materials and methods

Patients and tumor samples. The tumor samples used in the present study (19 specimens from 18 patients) were prospectively collected between January 2005 and December 2012. Clinical and pathological details are provided in Table I. All patients underwent surgery at the Department of Neurosurgery, Oslo University Hospital-Rikshospitalet and none of them had received chemotherapy or radiotherapy prior to surgery. Patient age ranged from eight months to 75 years at the time of the primary surgery. There were six female and 12 male patients, and all but three samples were taken from primary tumors. Both spinal and intracranial tumors were included, and all histopathological diagnoses were reviewed according to the WHO 2007 classification system (2). Progression was defined as tumor growth on magnetic resonance imaging (MRI) and recurrence was defined as the appearance of a new tumor by MRI. Progression-free survival (PFS) was defined as the time interval between initial surgery and radiologically proven tumor progression or recurrence. Overall survival (OS) was defined as the time interval between primary surgery and death.

G-banding and karyotyping. All tumor samples were processed for cytogenetic analysis using standard methods as described by Mandal (28). The chromosomes of the dividing cells were G-banded and a karyotype was established in accordance with ISCN 2009 (29). Karyotypes with four or fewer aberrations were defined as simple, whereas karyotypes with five or more aberrations were defined as complex.

DNA extraction and high-resolution comparative genomic hybridization (HR-CGH). DNA was extracted from the tumor samples using Maxwell 16 (Promega, Madison, WI, USA) (12 samples), standard phenol/chloroform method (four samples), or MagAttract DNA Mini M48 kit (Qiagen, Hilden, Germany). DNA sample quality and concentrations were measured and assessed using NanoVue Plus (GE Healthcare Life Sciences, Uppsala, Sweden).

CGH was performed as described by Kallioniemi et al (30) with modifications as published by Kirchhoff et al (31,32) and Kraggerud et al (33). Normal male human DNA (Promega) and the LoVo cell line (Sigma-Aldrich, St. Louis, MO, USA) were used as negative and positive controls. Inverted DAPI images were used to identify the chromosomes in 12 suitable metaphases of good quality, and the average green-to-red fluorochrome ratios with 99.5% confidence intervals were calculated along the length of each chromosome. In the cases where the G-banded karyotype was not near-diploid, a 95% confidence interval was used. These ratio profiles were compared with dynamic standard reference intervals as described by Ribeiro et al (34). Aberrations were recorded when the case and standard reference profiles, with their respective confidence intervals, did not overlap. A green-to-red ratio of 2.0 was defined as the threshold for amplifications. The short arms of acrocentric chromosomes (chromosome 13, 14, 15, 21 and 22) and the Y chromosome were not included in the analysis due to the known repetitive sequences in these chromosomal arms (30). The results of the HR-CGH analysis were described according to ISCN 2009 guidelines (29). We defined four or fewer chromosomes with imbalances as simple genomic changes, as opposed to complex genomic changes when five or more chromosomes were imbalanced.

Study approval and ethics. The study was approved by the Norwegian Regional Research Ethics Committee (reference number S-06046). Written, informed consent was obtained from 15 participants. The remaining three patients were included post mortem following permission from the Norwegian Directorate of Health. All tumor samples were collected from an approved biobank.

Results

Karyotypes were established from 17 samples, the remaining two samples failed in culture. Tissue was available for DNA extraction and HR-CGH analysis for 17 of 19 samples. Fifteen samples (79%) were analyzed using both methods. The karyotypes and HR-CGH results are presented in Table II and Fig. 1. Tumor recurrence and/or progression occurred in six patients after an average of 3.1 years (median 1.6 years). Three patients died; one of postoperative complications, one of ependymoma, and one of other disease. GTR was achieved at primary surgery in 14 of 18 patients (78%). For samples 9-1 and 9-2, which were taken from the primary and recurrent tumor from one patient, GTR was achieved at both the initial surgery and at the time of recurrence. These two tumors are thoroughly described in a previous case report (35).

G-banding and karyotyping. Twelve of 17 karyotypes (71%) were abnormal (Table II, Fig. 1): seven were near-diploid, three were near-triploid and two were near-tetraploid. Six (50%) karyotypes were simple, whereas the remaining six aberrant karyotypes had multiple chromosomal abnormalities. The number of aberrations in each abnormal sample ranged from one to 13. Eight of 12 (67%) abnormal samples displayed numerical aberrations only. Three samples (cases 3,
Table I. Clinical and pathological data of the 19 ependymoma samples from 18 patients.

| Case no. | Gender/age (years) | Localization | Histology \(^b\) | WHO grade | Primary tumor/ recurrence | Extent of resection\(^c\) | PFS/OS (years) | Current disease status\(^d\) |
|----------|-------------------|--------------|-----------------|-----------|--------------------------|-------------------------|----------------|-----------------------------|
| 1        | F/48              | IT           | E (melanotic variant) | II        | Primary                  | STR                     | 8.5\(^e\)   | AWD                         |
| 2        | M/44              | S            | MPE             | I         | Primary                  | GTR                     | 7.6\(^e\)   | NED                         |
| 3        | M/49              | ST           | AE              | III       | Recurrent                | GTR                     | 8.9          | NED                         |
| 4        | M/69              | IT           | MPE             | I         | Recurrent                | STR                     | 4.6/5.8      | DOD                         |
| 5        | F/47              | S            | E               | II        | Primary                  | GTR                     | 7.5\(^e\)   | NED                         |
| 6        | M/42              | S            | E               | II        | Primary                  | GTR                     | 6.9\(^e\)   | NED                         |
| 7        | M/53              | S            | E               | II        | Primary                  | GTR                     | 6.5\(^e\)   | NED                         |
| 8        | M/61              | IT           | SE              | I         | Primary                  | GTR                     | 6.1\(^e\)   | NED                         |
| 9-1      | M/38              | ST           | AE (giant cell type) | III       | Primary                  | GTR                     | 1.5          | NED                         |
| 9-2      |                   |              |                 |           |                          |                         |              |                             |
| 10       | M/75              | IT           | SE              | I         | Primary                  | GTR                     | 5.1\(^e\)   | NED                         |
| 11       | M/0.8             | ST           | E               | II or III | Primary                  | GTR                     | 5.1\(^e\)   | NED                         |
| 12       | M/42              | ST           | AE              | III       | Primary                  | GTR                     | 0.8/1.3      | DOE                         |
| 13       | F/46              | IT           | SE              | I         | Primary                  | GTR                     | 3.4\(^e\)   | NED                         |
| 14       | F/46              | IT           | E               | II        | Primary                  | GTR                     | 1.7          | AWD                         |
| 15       | F/0.9             | ST           | AE/GBM          | IV        | Primary                  | STR                     | 2.1\(^e\)   | AWD                         |
| 16       | F/1               | IT           | AE              | III       | Primary                  | STR                     | 1.2          | AWD                         |
| 17       | M/72              | IT           | E               | II        | Primary                  | GTR                     | 0.0/0.0      | DPC                         |
| 18       | M/67              | IT           | E with SE component | II       | Primary                  | GTR                     | 0.7\(^e\)   | NED                         |

Samples 9-1 and 9-2 were obtained from 1 patient. \(^a\)S, spinal; IT, infratentorial; ST, supratentorial. \(^b\)E, ependymoma; SE, subependymoma; AE, anaplastic ependymoma; MPE, myxopapillary ependymoma; GBM, glioblastoma. \(^c\)GTR, gross total resection; STR, subtotal resection. \(^d\)DOE, dead of ependymoma; AWD, alive with disease; NED, no evidence of disease; DOD, dead from other disease; DPC, dead of postoperative complications. \(^e\)Patient still alive with no evidence of disease progression (August 2013). M, male; F, female.

Figure 1. Gain and loss of genetic material by G-banding and HR-CGH in 18 ependymomas (sample 9-2 is not included in this graph). Green lines indicate gains, red lines indicate losses. The y-axis indicates the percentage of abnormal samples displaying certain aberrations; the x-axis indicates the chromosomes affected.
Table II. Karyotypes and HR-CGH results in 19 ependymoma samples from 18 patients.

| Case no. | Karyotype | HR-CGH results |
|----------|-----------|----------------|
| 1        | 68-70.XX-,X:,2,-6,+7,+9,+10,+11,+14,+15,-16[cp4]/46,XX[2] | rev ish enh (5p14p15, 7, 8q23, 9, 11, 14, 15) dim (X, 2, 6, 16) |
| 2        | 46,XY     | No material available |
| 3        | 89-94,XXYY,+2,-6;i(6)[p10]/cp11/46,XY[2] | rev ish enh (2), dim (6q) |
| 4        | 45,XY,-[6]/44, idem,-Y[16]/46,XY[1] | No material available |
| 5        | Culture fail | rev ish (17q21, 22q11) |
| 6        | 64-69,XXY,+Y,-3,+5,-6,+7,-11,+13,-14,+15,-16,-22 | rev ish enh (Xq21qter, 5, 7, 8, 13) dim (3, 6, 11, 16p11p13, 16q12q24, 22) |
| 7        | 69-70,XXY,+Y,+2,-5,+7,-8,+12,+14,+15,+18,+20,-21, [cp7]/46,XY[21]/nonclonal[1] | No imbalances |
| 8        | 46,XY     | No imbalances |
| 9-1      | 34-36,XY,-3,-6,-11,-12,-13,-14,-15,-17,-18,-22[cp6]/46,XY[10] | rev ish enh (2q22q32, 2q34q37, 4q12q21, 4q24q31, 4q32q34, 5p12p14, 5q11q12, 5q23q34, 6p23pter, 9q13q21) dim (3p13p14, 3p21p25, 3q12q13, 3q13q22, 3q24q27, 6p12, 6q22, 13q12q31, 14q11q21, 14q24q32, 15q15q21, 15q22q24, 17p11p13, 17q11q21, 17q22q24, 18q12q22) |
| 9-2      | 33-36,XY,-3,-6,-10,-11,-12,-13,-14,-18,-22[cp3] | rev ish enh (1p13p34, 1q21qter, 2, 4, 5, 5q13q31, 5q33q35, 7p13p22, 7q21q22, 7q22q36, 8p21pter, 8q12qter, 9q22q34, 20p12p13, 20q13, 21q12q22) dim (3p11, 3q27q28, 6p12p23, 6q25, 10p11p14, 10q21, 11p11p15, 11q3, 12p11p12, 12p13, 12q13q14, 12q4, 15q11q24, 17p, 17q11q25, 22q11q13) |
| 10       | 46,XY     | No imbalances |
| 11       | 46,XY[19] | rev ish enh (2p23pter) dim (1q23qter) |
| 12       | 44,XY,-10[14]/(13q22,-22)[12]/44, idem,der(14)(t[14]/(p13q22))[5]/39-43, idem, -8[14], -11[9], -12[4], -17[7], -18[4] | rev ish enh (7p) dim (8q11q22, 8q24, 10, 11q13, 12, 13, 17, 22q12qter) |
| 13       | Fail - no metaphases suitable for analysis | No imbalances |
| 14       | 46,XX[10] | rev ish enh (4, 5, 11, 14, 15, 17, 18, 19q13, 20p11p13, 20q11, 20q13) dim (6p12p22, 6q, 8, 10, 13) |
| 15       | 81-92,XXX,-X,del(2)q13-16p21~23,-10,+22[cp12]/46,XX[4] | rev ish enh (1p35p36, 2p16p23, 16q12, 16q21, 16q24) |
| 16       | 46,XX[21] | No imbalances |
| 17       | 45,XY,-[14]/46,XY[4] | rev ish dim (6) |
| 18       | 45,X,-Y[5]/46,XY[19]/nonclonal[4] | No imbalances |

Aberrations in bold were detected by both G-banding and HR-CGH.

12 and 15) showed a combination of structural and numerical genomic abnormalities. One sample had an unbalanced t(2;14)(p23q22) as its sole aberration (case 11). Three of the 12 abnormal karyotypes (25%) displayed a sole abnormality (cases 11, 17 and 18), but none of these were recurrent. None of the structural rearrangements occurred in more than one tumor. The most common numerical aberration was loss of chromosome 6, which was noted in six tumor samples, two of which were obtained from the same patient (primary tumor and recurrence; cases 9-1 and 9-2). Five tumors from four patients showed loss of chromosome 22. The overall gain/loss profile of 11 karyotypically abnormal tumor samples (Fig. 1; the recurrent tumor from the patient from whom we also had primary tumor material, case 9-1, is excluded) showed that the long arm of chromosome 6 was lost in six tumors (55%). This was mostly due to monosomy 6, but in one case because of an
iso chromosome 6p with loss of chromosome arm 6q. Material from 14q (14q24-pter) was lost in five (45%) samples; this was due to loss of the entire chromosome 14 in three tumors and to unbalanced structural rearrangements in two.

**HR-CGH analysis.** HR-CGH analysis was informative in all 17 samples from which DNA was available. Twelve of 17 samples (71%) had genomic imbalances, and all analyzed chromosomes were affected in one or more samples. Gains were noted in nine and losses in 12 samples. No amplifications were found. The average number of aberrations per abnormal sample was 12, and gains (average 5.3) were slightly less common than losses (average 6.9). Five of 12 samples (42%) had simple genomic changes whereas the remaining seven (58%) were genomics complex with an average of 12 affected chromosomes per sample. The most common genomic imbalances in 11 tumor samples (Fig. 1; the recurrent tumor from the patient in which we also had material from the primary tumor, case 9-2, is again excluded) were copy number loss involving 6q (55%) and 6p (45%) and gain involving 5p (46%).

**Genomic aberrations in anatomical subgroups.** Karyotypes were successfully obtained from three of four spinal tumors. One of them was normal (case 2) whereas the other two (cases 6 and 7) had near-triploid, complex karyotypes with numerical abnormalities only. HR-CGH was performed on three of four spinal lesions and all three were abnormal. Two tumors displayed complex genomic aberrations and all three had copy number losses at band 22q11.

Eight of nine (89%) infratentorial tumors were successfully karyotyped. Four of these were cytogenetically normal and one tumor (case 18) showed Y loss only. Two of the remaining three abnormal tumors (cases 4 and 17) had simple, near-diploid karyotypes with loss of chromosome 6. The last tumor (case 1) had a complex, near-triploid karyotype with several numerical aberrations. DNA material was available for HR-CGH analysis for eight of nine (89%) tumors. Three of these (38%; cases 1, 14 and 17) were normal, of which two harbored complex genomic imbalances. Genomic losses at 6p and 6q were found by HR-CGH in all three abnormal infratentorial tumors.

All six supratentorial tumors were karyotypically normal and in three of five (60%) tumors loss of material from 14q was noted. All four tumors harboring structural rearrangements were supratentorial. HR-CGH results from all six supratentorial samples were abnormal. When excluding the recurrent tumor (case 9-2), three of five (60%) cases displayed simple genomic changes.

**Genomic aberrations and tumor grade.** Sixteen tumors were assessed; five grade I tumors (cases 2, 4, 8, 10 and 13), seven grade II tumors (cases 1, 5, 6, 7, 14, 17 and 18), and four grade III tumors (cases 3, 9-1, 12 and 16). Case 11 was not included due to its uncertain WHO grade and case 9-2 was not assessed because its corresponding primary tumor (case 9-1) was already included in the grade III group. Case 15 was excluded due to its histology (anaplastic ependymoma with prominent glioblastoma features).

Four of five (80%) grade I tumors were informative by G-banding. Three of these (75%) were karyotypically normal, whereas the remaining tumor (case 4) had a simple karyotype with monosomy 6. DNA was available for HR-CGH analysis in three of five tumors and all three were normal.

Six of seven grade II lesions were informative by G-banding. One of these (17%) had a normal karyotype. There were no structural chromosomal aberrations found in this group. The most common numerical aberrations were +7, +15 and -6 (three cases each; 50%). HR-CGH analyses were performed on all seven grade II ependymomas: one tumor (14%) did not harbor any genomic imbalances, two tumors (29%) displayed simple genomic imbalances, and four (57%) had complex HR-CGH profiles with an average of 17 aberrations per sample.

G-banded karyotypes were obtained from all four grade III ependymomas. One karyotype was normal, one tumor had a simple karyotype and two tumors had complex karyotypes. All four tumors were informative by HR-CGH. One of them had a normal profile, one had simple changes, whereas the remaining two tumors (cases 9-1 and 12) had complex profiles.

**Genomic aberrations and biological tumor behavior.** Tumor samples from patients with known disease progression were compared to those with stable disease. Six patients were included (cases 3, 4, 9-1, 12, 14 and 16) in the progression group, eleven patients (cases 1, 2, 5, 6, 7, 8, 10, 11, 13, 15 and 18) in the ‘no progression’ group, whereas one patient (case 17) died of postoperative complications and was excluded. There were four grade III, one grade II, and one grade I tumor within the progression group.

The progression group was karyotypically heterogeneous. Two patients (33%) had a normal karyotype, two (cases 3 and 4) had karyotypes with simple changes, and the remaining two abnormal tumors were karyotypically complex. Aberrations leading to loss of 6q were found in three of four (75%) abnormal karyotypes. By HR-CGH, one tumor had a normal profile, one had a simple profile, and three tumors had complex changes. The most common imbalance by CGH was loss of material from band 6q22 which was noted in three of four (75%) abnormal samples.

The average follow-up for the 11 patients in the ‘no recurrence’ group was 5.4 years (median 6.1). Karyotypes were successfully obtained from nine of 11 (82%) tumors. Three of these were normal, three were karyotypically simple, while the remaining three samples had complex karyotypes. The most common karyotypic aberrations in this group were +7 and +15 as well as loss of material from the distal end of chromosome 14. These changes occurred in three tumors (50%) each. DNA was available for HR-CGH in all but one of the cases in this group of tumors. Four of them (40%) were normal. Among the six remaining cases there were three samples with simple and three samples with complex profiles. The most common imbalances were gains at 5p and 7p/7q as well as losses from 16p/16q and 22q, which were all found in three (50%) of the six abnormal samples.

**Discussion**

There was good overall concordance between HR-CGH and G-banding results in the 19 ependymomas we examined (Figs. 1 and 2; Table II). Of the 15 tumor samples analyzed by both methods, three (20%) were normal by both G-banding and
of an unknown type. Notably, Korshunov et al (38) proposed a risk stratification scheme for ependymomas based on cytogenetics with tumors harboring monosomy 6 (among other aberrations) being significantly associated with an excellent progression-free and overall survival. These findings were validated in an independent cohort of 170 patients. Some smaller studies have also investigated the impact of 6q deletions on prognosis. Moronanu et al (45) found that 6q25.3 deletions in pediatric, intracranial grade III ependymomas were significantly associated with longer overall survival. In contrast, Rajaram et al (46) found that 6q23 loss, detected by fluorescent in situ hybridization (FISH), was associated with disease progression in a mixed patient population. The present series is small and prognostic conclusions cannot be drawn. The potential of 6q loss as a prognostic marker is still in need of prospective evaluation in future studies (47). 5p gain is also a known abnormality in ependymomas and was detected in five of 12 tumors (42%) with copy number changes. Kilday et al (23) found that gain of chromosome 5 or chromosome arm 5p was reported in ~25% of adult ependymomas analyzed by CGH. In the present study, this aberration was not typical of any anatomical subgroup, but four of five (80%) tumors with 5p gain were grade II ependymomas.

Pediatric ependymomas appear to be genetically distinct from adult tumors; 1q gain was reported to be more common in children in spite of generally fewer genomic imbalances or even balanced genomic profiles by CGH (23,38,48). 1q gain was found to be associated with poor survival for intracranial ependymoma patients (38,47). In our series, 1q gain was not found in any tumor, neither adult nor pediatric. The three pediatric ependymomas all had simple karyotypes and few imbalances by HR-CGH. One of them was normal both by karyotyping and HR-CGH (case 16). Notably, this was a clinically aggressive tumor which progressed after 1.2 years in spite of active oncological treatment. Another pediatric tumor (case 15) was described by the neuropathologist as an anaplastic glioma with both astrocytic and ependymal features. The final diagnosis was ‘anaplastic glioma, WHO grade IV, most likely anaplastic ependymoma’ and the patient was treated according to ependymoma protocols. The karyotype was near-tetraploid but simple, with an interstitial 2p deletion, gain of chromosome 22, and loss of chromosome 10. The HR-CGH analysis confirmed the 2p deletion and also showed loss of 1p and 16q. Loss of chromosome 10 is a typical finding in glioblastomas (26,49) but was not frequent in the current ependymoma series. Furthermore, none of the most common aberrations in this series (Fig. 1), such as 6q loss, 5p gain, 7p/7q gain or 22q loss, were detected in this particular tumor. Glioblastomas most often have complex karyotypes with multiple structural and numeric abnormalities (49). Based on the cytogenetic findings, one might argue that this case bears more resemblance to astrocytomas/glioblastomas than to ependymomas.

Four tumors in this series (cases 3, 11, 12 and 15) harbored structural chromosomal rearrangements. Among these, case 11 is of particular interest. This tumor had a der(14)t(2;14) as its sole aberration by G-banding. The unbalanced translocation was reflected in the HR-CGH profile which displayed loss of material at 14q23qter but also gain of material at 2p23pter. Notably, this breakpoint region on chromosome 2 (2p23) was also involved in an interstitial 2p deletion found
in another tumor (case 15). It is possible that the observed rearrangements affect putative cancer-related genes located in this chromosomal region. Thus, 2p23 is an area of interest for future molecular studies.

The present study is the first to combine karyotypic and CGH analyses of ependymomas. It provides an overview of the ependymoma genome and is a significant contribution to existing cytogenetic knowledge on these rare tumors. 6q loss and 5p gain were found to be the most common chromosomal aberrations in our heterogeneous patient population. The significance of these findings requires further analysis in larger studies.

Acknowledgements

The present study was supported by grants from the Norwegian Cancer Society and The Norwegian Children's Cancer Fund (Barnekreftforeningens forskningsfond-Forsvar mot kreft). It was partly supported by the Research Council of Norway through its Centres of Excellence funding scheme, project number 179571. The authors thank Hanne-Sofie Spanneng Dahlback, Hege Kilen Andersen and Lisbeth Haugom for data management and technical assistance.

References

1. McGuire CS, Sainani KL and Fisher PG: Incidence patterns for ependymoma: a Surveillance, Epidemiology, and End Results study. J Neurosurg 110: 725-729, 2009.
2. McLendon RE, Schiffer D, Rosenblum MK, Wiestler OD, Kros JM, Korsunov A and Ng HK: Ependymal tumours. In: WHO Classification of Tumours of the Central Nervous System. 4th edition. Louis DN, Ohgaki H, Wiestler OD and Cavenee WK (eds.) International Agency for Research on Cancer (IARC), Lyon, pp69-80, 2007.
3. Reni M, Gatta G, Mazza E and Vecht C: Ependymoma. Crit Rev Oncol Hematol 63: 81-89, 2007.
4. Dolecek TA, Proper JM, Stroup NE and Kruchko C: CBTRUS Statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009. Neuro Oncol 14 (Suppl 5): v1-v49, 2012.
5. Sant M, Minicozzi P, Lagorio S, Borge Johannesen T, Marcos-Gragera R and Francis ca: Survival of European patients with central nervous system tumors. Int J Cancer 113: 193-199, 2007.
6. Gilbert MR, Ruda R and Soffietti R: Ependymomas in adults. Curr Neurol Neurosci Rep 10: 240-247, 2010.
7. Surawicz TS, McCarthy BJ, Kupelian V, Jukich PJ, Bruner JM and Chamberlain MC: Ependymoma. Curr Opin Neurol 21: 754-761, 2008.
8. Chamberlain MC: Ependymomas. Curr Neurol Neurosci Rep 3: 193-199, 2003.
9. Zarachoulis S and Moreno L: Ependymoma: an update. J Child Neurol 24: 1431-1438, 2009.
10. Ruda R, Gilbert M and Soffietti R: Ependymomas of the adult: molecular biology and treatment. Curr Opin Neurol 21: 754-761, 2008.
11. Crocetti E, Trama A, Stiller C, et al: Epidemiology of glial and non-glial brain tumours in Europe. Eur J Cancer 48: 1532-1542, 2012.
12. Barnholtz-Sloan JS, Sloan AE and Schwartz AG: Relative survival rates and patterns of diagnosis analyzed by time period for individuals with primary malignant brain tumor, 1973-1997. J Neurosurg 99: 458-466, 2003.
13. Rodriguez D, Cheung MC, Housri N, Quiñones-Hinojosa A, Camphausen K and Koniaris LG: Outcomes of malignant CNS ependymomas: an examination of 2408 cases through the Surveillance, Epidemiology, and End Results (SEER) database (1973-2005). J Surg Res 156: 340-351, 2009.
14. Villano JL, Parker CK and Dolecek TA: Descriptive epidemiology of ependymal tumors in the United States. Br J Cancer 108: 2367-2371, 2013.
15. Yang J, Nagasawa DT, Kim W, Spasic M, Trang A, Lu DC and Martin NA: Chromosomal abnormalities and prognostic markers for intracranial and spinal ependymomas. J Clin Neurosci 19: 779-785, 2012.
16. Mettellus P, Guyotat J, Chinot O, et al: Adult intracranial WHO grade II ependymomas: long-term outcome and prognostic factor analysis in a series of 114 patients. Neuro Oncol 12: 976-984, 2010.
17. Korshunov A, Golanov A, Sycheva R and Timirgaz V: The histologic grade is a main prognostic factor for patients with intracranial ependymomas treated in the microneurosurgical era: analysis of 258 patients. Cancer 100: 1230-1237, 2004.
18. Reni M, Brandes AA, Vavassori V, et al: A multicenter study of the prognosis and treatment of adult brain ependymal tumors. Cancer 100: 1221-1229, 2004.
19. Mettellus P, Barrie M, Figarella-Branger D, et al: Multicentric French study on adult intracranial ependymomas: prognostic factors analysis and therapeutic considerations from a cohort of 152 patients. Brain 130: 1338-1349, 2007.
20. Godfraind C: Classification and controversies in pathology of ependymomas. Childs Nerv Syst 25: 1185-1193, 2009.
21. Massimino M, Buttarelli FR, Antonelll M, Gandola L, Modena P and Giangaspero F: Intracranial ependymoma: factors affecting outcome. Future Oncol 5: 207-216, 2009.
22. Andreiuolo F, Ferreira C, Puget S and Grill J: Current and evolving knowledge of prognostic factors for pediatric ependymomas. Future Oncol 9: 183-191, 2013.
23. Kilday JP, Rahman R, Dyer S, Ridley L, Lowe J, Coyle B and Grundy R: Pediatric ependymoma: biological perspectives. Mol Cancer Res 7: 765-786, 2009.
24. Mettelman F, Johansson B and Menters F: Mitelman Database of Chromosome Aberrations and Gene Fusions in Cancer. Available at: http://cgap.nci.nih.gov/Chromosomes/Mitelman. Accessed May 13, 2013.
25. Mazewski C, Soukop S, Ballard E, Gotvalls B and Lampkin B: Karyotype studies in 18 ependymomas with literature review of 107 cases. Cancer Genet Cytofgenet 113: 1-8, 1999.
26. Heim S and Mitelman F: Cancer Cytogenetics. 3rd edition. John Wiley & Sons, Hoboken, NJ, 2009.
27. Mack SC and Taylor MD: The genetic and epigenetic basis of ependymoma. Childs Nerv Syst 25: 1195-1201, 2009.
28. Mandahl N: Methods in solid tumor cytogenetics. In: Human Cytogenetics - Malignancy and Acquired Abnormalities. 3rd edition. Rooney DE (ed). Oxford University Press, Oxford, pp65-203, 2001.
29. Shaffer LG, Slovak ML and Campbell LJ: ISCN: An International System for Human Cytogenetic Nomenclature. Karger, Basel, 2009.
30. Kallioniemi OP, Kallioniemi A, Piper J, Isola J, Waldman FM, Gray JW and Pinkel D: Optimizing comparative genomic hybridization for analysis of DNA sequence copy number changes in solid tumors. Genes Chromosomes Cancer 10: 231-243, 1994.
31. Kirchhoff M, Gerdes T, Maahr J, Rose H, Bentz M, Dohner H and Lundsteen C: Deletions below 10 megabases are detected in comparative genomic hybridization by standard reference intervals. Genes Chromosomes Cancer 25: 410-413, 1999.
32. Kirchhoff M, Gerdes T, Rose H, Maahr J, Ottesen AM and Lundsteen C: Detection of chromosomal gains and losses in comparative genomic hybridization analysis based on standard reference intervals. Cytometry 31: 163-169, 1998.
33. Kirchhoff M, Gerdes T, Rose H, Maahr J, Ottesen AM and Lundsteen C: Detection of chromosomal gains and losses in comparative genomic hybridization analysis based on standard reference intervals. Genes Chromosomes Cancer 25: 410-413, 1999.
34. Kraggerud SM, Szymanska J, Abeler VM, et al: DNA copy number changes in malignant ovarian germ cell tumors. Cancer Res 60: 3025-3030, 2000.
35. Ribeiro FR, Jeronimo C, Henrique R, Fonseca D, Oliveira J, Lothe RA and Teixeira MR: 8q gain is an independent predictor of poor survival in diagnostic needle biopsies from prostate cancer suspects. Clin Cancer Res 12: 3961-3970, 2006.
36. Dahlback HS, Brandal P, Krossnes BK, et al: Multiple chromosomal monosomies are characteristic of giant cell ependymoma. J Pathol 210: 2042-2046, 2011.
37. Hirose Y, Aldape K, Bollen A, et al: Chromosomal abnormalities subdivide ependymal tumors into clinically relevant groups. Am J Pathol 158: 1137-1143, 2001.
38. Huang B, Starostik P, Schrast H, Krauss J, Sorensen N and Roggendorf W: Human ependymomas reveal frequent deletions on chromosomes 6 and 9. Acta Neuropathol 106: 357-362, 2003.
38. Korshunov A, Witt H, Hielscher T, et al: Molecular staging of intracranial ependymoma in children and adults. J Clin Oncol 28: 3182-3190, 2010.

39. Reardon DA, Entrekin RE, Sublett J, et al: Chromosome arm 6q loss is the most common recurrent autosomal alteration detected in primary pediatric ependymoma. Genes Chromosomes Cancer 24: 230-237, 1999.

40. Zeller C, Hinzmann B, Seitz S, et al: SASH1: a candidate tumor suppressor gene on chromosome 6q24.3 is downregulated in breast cancer. Oncogene 22: 2972-2983, 2003.

41. Rimkus C, Martini M, Friederichs J, et al: Prognostic significance of downregulated expression of the candidate tumour suppressor gene SASH1 in colon cancer. Br J Cancer 95: 1419-1423, 2006.

42. Suarez-Merino B, Hubank M, Revesz T, et al: Microarray analysis of pediatric ependymoma identifies a cluster of 112 candidate genes including four transcripts at 22q12.1-q13.3. Neuro Oncol 7: 20-31, 2005.

43. Korshunov A, Neben K, Wrobel G, et al: Gene expression patterns in ependymomas correlate with tumor location, grade, and patient age. Am J Pathol 163: 1721-1727, 2003.

44. COSMIC: Catalogue of somatic mutations in cancer - Cancer gene census. Available at: http://cancer.sanger.ac.uk/cancergene/census/. Accessed August 20, 2013.

45. Monoranu CM, Huang B, Zangen IL, et al: Correlation between 6q25.3 deletion status and survival in pediatric intracranial ependymomas. Cancer Genet Cytogenet 182: 18-26, 2008.

46. Rajaram V, Gutmann DH, Prasad SK, Mansur DB and Perry A: Alterations of protein 4.1 family members in ependymomas: a study of 84 cases. Mod Pathol 18: 991-997, 2005.

47. Witt H, Korshunov A, Pfister SM and Milde T: Molecular approaches to ependymoma: the next step(s). Curr Opin Neurol 25: 745-750, 2012.

48. Puget S, Grill J, Valent A, et al: Candidate genes on chromosome 9q33-34 involved in the progression of childhood ependymomas. J Clin Oncol 27: 1884-1892, 2009.

49. Dahlback HS, Brandal P, Meling TR, Gorunova L, Scheie D and Heim S: Genomic aberrations in 80 cases of primary glioblastoma multiforme: Pathogenetic heterogeneity and putative cytogenetic pathways. Genes Chromosomes Cancer 48: 908-924, 2009.